Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
- PMID: 27654854
- DOI: 10.1016/j.jacc.2016.09.004
Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
Abstract
Background: The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF).
Objectives: The TACTICS-HF (Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address the acute use of tolvaptan to improve congestion in AHF.
Methods: The TACTICS-HF study randomized patients (n = 257) within 24 h of AHF presentation in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients considered responders at 24 h. Secondary endpoints included symptom improvement, changes in renal function, and clinical events.
Results: Dyspnea relief by Likert scale was similar between groups at 8 h (25% moderately or markedly improved with tolvaptan vs. 28% placebo; p = 0.59) and at 24 h (50% tolvaptan vs. 47% placebo; p = 0.80). Need for rescue therapy was also similar at 24 h (21% tolvaptan, 18% placebo; p = 0.57). The proportion defined as responders at 24 h (primary study endpoint) was 16% for tolvaptan and 20% for placebo (p = 0.32). Tolvaptan resulted in greater weight loss and net fluid loss compared with placebo, but tolvaptan-treated patients were more likely to experience worsening renal function during treatment. There were no differences in in-hospital or post-discharge clinical outcomes.
Conclusions: In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen did not improve the number of responders at 24 h, despite greater weight loss and fluid loss. (Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).
Keywords: acute heart failure; decongestion; outcomes; strategies; volume overload.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Tolvaptan in Acute Heart Failure: Time to Move On.J Am Coll Cardiol. 2017 Mar 21;69(11):1407-1408. doi: 10.1016/j.jacc.2016.09.005. Epub 2016 Sep 18. J Am Coll Cardiol. 2017. PMID: 27654853 No abstract available.
-
Heart failure: No early benefits of adjunct therapy with tolvaptan for acute heart failure.Nat Rev Cardiol. 2017 May;14(5):256. doi: 10.1038/nrcardio.2017.46. Epub 2017 Mar 31. Nat Rev Cardiol. 2017. PMID: 28361975 No abstract available.
Similar articles
-
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.J Am Coll Cardiol. 2017 Mar 21;69(11):1409-1419. doi: 10.1016/j.jacc.2016.12.035. J Am Coll Cardiol. 2017. PMID: 28302292 Clinical Trial.
-
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.Circ Heart Fail. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259. Circ Heart Fail. 2015. PMID: 26374918 Review.
-
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384438 Clinical Trial.
-
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.JAMA. 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963. JAMA. 2004. PMID: 15113814 Clinical Trial.
-
Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.Int J Mol Sci. 2016 Jan 14;17(1):105. doi: 10.3390/ijms17010105. Int J Mol Sci. 2016. PMID: 26784173 Free PMC article. Review.
Cited by
-
Optimal diuretic strategies in heart failure.Ann Transl Med. 2021 Mar;9(6):517. doi: 10.21037/atm-20-4600. Ann Transl Med. 2021. PMID: 33850914 Free PMC article. Review.
-
Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction.Int J Cardiol Heart Vasc. 2018 Oct 10;21:69-73. doi: 10.1016/j.ijcha.2018.09.008. eCollection 2018 Dec. Int J Cardiol Heart Vasc. 2018. PMID: 30345343 Free PMC article.
-
Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.J Int Med Res. 2019 Nov;47(11):5414-5425. doi: 10.1177/0300060519882221. Epub 2019 Nov 4. J Int Med Res. 2019. PMID: 31680601 Free PMC article.
-
Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients.Fujita Med J. 2023 Feb;9(1):8-11. doi: 10.20407/fmj.2021-005. Epub 2022 May 25. Fujita Med J. 2023. PMID: 36789131 Free PMC article.
-
Dyspnea Measurement in Acute Heart Failure: A Systematic Review and Evidence Map of Randomized Controlled Trials.Front Med (Lausanne). 2021 Oct 6;8:728772. doi: 10.3389/fmed.2021.728772. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34692723 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous